report revenu y/i vs consensu non-gaap
ep y/i vs consensu increas tighten
revenu guidanc non-gaap ep guidanc light sale trend share
buyback trade new ep estim view share under-valued
product sale y/i beat consensu estim sensipar
kyproli vs drove much upsid
repatha vs anoth quarter healthi growth q/q
y/i sale growth unit volum q/q y/i temper price
concess manag reiter optim bright futur repatha driven
expand label sever geographi improv access follow negoti
payer call tonight manag disclos agreement made
other simplifi util manag criteria exchang
better rebat estim sum payer account repatha
commerci revenu contract go effect juli access
improv like drive volum growth though net price continu
declin launch aimovig still earli day prescript repres free
drug engag success payer estim
live alreadi cover util criteria expect requir patient
fail gener therapi physician attest
sensipar follow-on product parsabiv second quarter sale q/q
launch well fact cannib sale predecessor denosumab franchis
prolia/xgeva continu deliv doubl digit y/i growth intend
increas market invest prolia maintain strong trajectori sale enbrel
vs neulasta/neupogen vs aranesp
vs gener in-lin neulasta like begin
face headwind biosimilar competit follow approv fulphila
howev market use onpro devic util expand
devic launch sever european countri confid abil
defend much share upsid non-gaap ep vs reflect higher
product sale lower tax rate vs reduc share count follow
pleas see page report import disclosur
view better-than-averag pharmaceut compani back biolog
franchis good longev superior geograph mix centric least averag
reason pipelin despit attribut trade discount
averag pharma price-to-earnings multipl believ discount best explain fear
biosimilar competit lack clariti key pipelin asset expect amgen
share outperform competit threat wane relat prospect newer
enbrel patent hear court case
launch amjevita biosimilar humira
phase data bite antibodi
ep growth
price-to-earnings ratio expand toward
revenu growth greater
revenu growth lower project
price-to-earnings ratio pharma group undergo
pipelin contribut substanti
valu model
fail rais dividend pursu
biosimilar launch exceed
among world largest biotechnolog compani product sale
approxim revenu deriv biolog
unlik experi gener competit forese futur major brand includ
enbrel sale neupogen/neulasta denosumab franchis brand
xgeva cancer prolia osteoporosi sale aranesp/epogen
amgen continu invest six therapeut area focu leverag
genet capabl decod databas within portfolio newer product
favor repatha antibodi signific potenti treat sever
hypercholesterolemia repatha fourier outcom data expect drive growth
prescrib recent agreement payor could open access patient
increas revenu guidanc base upon
potenti sensipar retain exclus improv outlook
repatha high end guidanc appear achiev non-gaap ep guidanc
also increas look conserv us
light improv revenu outlook greatli reduc share count amgen
guid addit share repurchas revenu
non-gaap ep estim top end guidanc non-
gaap ep estim increas price target base
multipl project earn increas
view respect financi report believ continu financi
engin share buyback cost control tax save posit
beat nearer-term financi expect investor concern number
major franchis includ neulasta sensipar face competit moder
stock perform seem possibl continu success defend share
declin simpli bad fear howev substanti out-performance
depend upon abil newer product repatha aimovig gain
greater traction drive meaning top-lin growth encourag repatha
earli trajectori wake broader outcom orient label hope
increas uptak access continu improv aimovig prescript trend
first coupl month market solid impli potenti
capit first mover advantag larg migrain market build
success last sever month share could benefit substanti multipl
among world largest biotechnolog compani product sale
flat y/i deriv revenu superior
market drug price moreov approxim revenu deriv
biolog unlik experi substitut competit
forese futur major brand includ enbrel sale
neupogen/neulasta xgeva/prolia denosumab aranesp/epogen
near complet seri restructur design expand
oper margin appear track least
meet financi target includ commit return cash
sharehold form dividend stock buyback expect share
outperform compani increas dividend post upsid consensu revenu
ep expect receiv credit newer product repatha
antibodi sever hypercholesterolemia model non-gaap ep
growth commit aggress share repurchas plan
boost ep growth near term
cog percent sale
 percent sale
sg percent sale
cowen compani
enbrel patent hear court case versu sanofi
potenti launch gener sensipar
european approv decis even romosozumab postmenopaus osteoporosi
european approv decis kyproli variat updat label includ os data
launch amjevita biosimilar humira europ
possibl aha updat treatment guidelin
phase data bite antibodi aml mm respect
phase ii data antibodi migrain prevent
new district court trial praluent infring
cowen compani
cowen compani
growth growth aranesp y/i erythropoietin enbrel growth sale g-csf growth dmab growth kyproli growth product sale growth revenu growth good sold margin develop margin product incom growth growth ep includ stock share outstand ep exclud fasb abp stock compens expens merger-rel item ep cowen
cowen compani
 aranesp y/i erythropoietin enbrel growth sale g-csf growth dmab growth kyproli growth product sale growth revenu growth good sold margin develop loss affili margin product incom growth share outstand ep exclud fasb abp stock compens expens merger-rel item ep cowen
cowen compani
oper activitiesnet acquir in-process d- depreci base compens defer incom pp impairments- chang work capit less provid oper invest activ purchas /sale /proce market net use invest financ activitiesproce issuanc common common net provid financ cash cash cash equival begin cash equival end summari oper exclud non-recur item cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
base busi compris mostli older biolog could experi biosimilar
competit impact difficult ass paid reason
sum acquir lead candid kyproli drug uncertain
sale potenti manag outlin strategi return cash sharehold
deviat plan could creat stock weak volatil much perceiv
valu within pipelin focus anti-cgrp anti-sclerostin
associ regulatori commerci risk
